Halozyme director sells 18,996 shares under plan

HALO director Matthew L. Posard disclosed 18,996 HALO shares sold on September 16, 2026 under a pre-arranged Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

HALOZYME THERAPEUTICS, INC. (HALO) director Matthew L. Posard reported selling a total of 18,996 shares of common stock on September 16, 2026 in four open-market transactions. The sales, at weighted average prices between about $106 and $109 per share, were made under a Rule 10b5-1 trading plan adopted June 15, 2026.

Insider Trade Summary 10b5-1

Net Seller: 18,996 shares

Net Sell 4 txns

Insider Posard Matthew L.

Role Director

Sold 18,996 shs ($2.05M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	3,100	$106.132	$329K
Sale	Common Stock F1, F3	3,000	$106.828	$320K
Sale	Common Stock F1, F4	8,896	$108.04	$961K
Sale	Common Stock F1, F5	4,000	$108.991	$436K

Holdings After Transaction: Common Stock — 58,839 shares (Direct)

Footnotes (5)

1. F1. The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1.
2. F2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $105.550 to $106.540. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
3. F3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.580 to $107.310. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
4. F4. Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.600 to $108.450. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
5. F5. Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.605 to $109.460. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Key Figures

Total shares sold: 18,996 shares First transaction: 3,100 shares at $106.132 per share Second transaction: 3,000 shares at $106.828 per share +3 more

6 metrics

Total shares sold 18,996 shares Aggregate HALO common stock sales by director on September 16, 2026

First transaction 3,100 shares at $106.132 per share Weighted average price; prices ranged from $105.550 to $106.540

Second transaction 3,000 shares at $106.828 per share Weighted average price; prices ranged from $106.580 to $107.310

Third transaction 8,896 shares at $108.040 per share Weighted average price; prices ranged from $107.600 to $108.450

Fourth transaction 4,000 shares at $108.991 per share Weighted average price; prices ranged from $108.605 to $109.460

Rule 10b5-1 plan adoption date June 15, 2026 Date the written trading plan governing these sales was adopted

Key Terms

Rule 10b5-1, weighted average sales price per share, trading plan, open market or private transaction

4 terms

Rule 10b5-1 regulatory

"adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

weighted average sales price per share financial

"Represents a weighted average sales price per share. The shares were sold"

trading plan regulatory

"sales reported on this Form 4 were made pursuant to a written trading plan"

A trading plan is a written set of rules an investor follows about what to buy or sell, when to enter and exit positions, and how much risk to accept—like a travel itinerary that maps the route, stops, and budget before a trip. It matters because it helps remove emotional decisions during market swings, enforces discipline, and makes performance easier to review and improve, reducing the chance of costly impulsive moves.

open market or private transaction market

"Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the insider trading in HALO stock in this Form 4?

The filing reports transactions by Matthew L. Posard, a director of HALOZYME THERAPEUTICS, INC. The reported trades involve the company’s common stock and are disclosed as open-market sales on September 16, 2026.

How many HALO shares did Matthew L. Posard sell on September 16, 2026?

Matthew L. Posard sold an aggregate of 18,996 shares of HALO common stock on September 16, 2026, as reported across four separate sale transactions in this Form 4 filing.

At what prices were the HALO shares sold in this Form 4?

The reported weighted average prices were $106.132, $106.828, $108.040, and $108.991 per share. Footnotes state actual sale prices ranged from $105.550 to $109.460 across the four transactions.

Were the HALO stock sales made under a Rule 10b5-1 trading plan?

Yes. A footnote states the sales were made pursuant to a written trading plan adopted by Matthew L. Posard on June 15, 2026 in accordance with Rule 10b5-1, and the filing’s Rule 10b5-1 checkbox is affirmed.

How many separate sale transactions are reported for HALO in this Form 4?

The Form 4 reports four separate open-market sale transactions of HALO common stock on September 16, 2026, with share amounts of 3,100, 3,000, 8,896, and 4,000, respectively.

What does the weighted average sales price mean in this HALO Form 4?

For each transaction, the reported price is a weighted average sales price per share. Footnotes explain that the actual trades occurred across specified price ranges, and detailed per-price share counts are available from the company or SEC staff on request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 05:20 PM Accepted by SEC EDGAR 09/17/2026 - 05:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Posard Matthew L.

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2026		S(1)		3,100	D	$106.132(2)	74,735	D
Common Stock	09/16/2026		S(1)		3,000	D	$106.828(3)	71,735	D
Common Stock	09/16/2026		S(1)		8,896	D	$108.04(4)	62,839	D
Common Stock	09/16/2026		S(1)		4,000	D	$108.991(5)	58,839	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1.

2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $105.550 to $106.540. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.580 to $107.310. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

4. Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.600 to $108.450. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

5. Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.605 to $109.460. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)